When was Aadi Bioscience founded?

Aadi Bioscience was founded in 2008 and raised its 1st funding round 4 years after it was founded.

Where is Aadi Bioscience located?

Aadi Bioscience is headquartered in Los Angeles, United States. It is registered at Saint Cloud, Florida.

How many employees does Aadi Bioscience have?

As of Jul 31, 2026, the latest employee count at Aadi Bioscience is 55.

Is Aadi Bioscience a funded company?

Aadi Bioscience is a funded company, having raised a total of $23M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 26, 2012.

When was the latest funding round of Aadi Bioscience?

Aadi Bioscience's latest funding was a $***** Post IPO round on Mar 04, 2025, with participation from 0 investor.

What is the annual revenue of Aadi Bioscience?

Annual revenue of Aadi Bioscience is between $10M and $50M as on Dec 31, 2023

Where does Aadi Bioscience rank among its competitors?

Aadi Bioscience ranks 88th amongst 3272 active competitors, of which 1116 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Aadi Bioscience?

Aadi Bioscience's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Aadi Bioscience - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Precision medicine company improving lives with mTOR-driven disease therapies. The company focuses on realizing the potential of mTOR inhibition through precision medicine and albumin-bound nanoparticle technology. It aims to improve the lives of people with mTOR-driven diseases by addressing the limitations of current mTOR inhibitors. The company leverages genomic profiling technology to identify patients most likely to benefit from mTOR inhibition. The company is dedicated to advancing therapies for advanced malignant PEComa and other pipeline opportunities. The company is committed to patient advocacy and providing resources for healthcare professionals. The company is a pharmaceutical company focused on research and development of targeted therapies.

Website: www.aadibio.com/
Social
Registered Address: Saint Cloud, Florida

Key Metrics

Founded Year

2008

Location

Los Angeles, United States

Stage

Public

Total Funding

$23M in 5 rounds

Latest Funding Round

Post IPO, Mar 04, 2025, $*****

Investors

Hermed Capital & 14 more

Ranked

88^th among 3272 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2023

Employee Count

55 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2976 more

Exit Details

Public

View Aadi Bioscience's full profile

Aadi Bioscience is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Aerpio Pharmaceuticals, Inc. CIN: 1422142 , United States, Active		$1M - $10M (As on Dec 31, 2025)	-	-
Aadi Bioscience Inc CIN: 453536176 , United States, Active	Dec 31, 1999	-	40 (As on Dec 31, 2024)	-
AADI INC CIN: 593106566 , United States, Active	Dec 26, 999	-	15 (As on Dec 31, 2024)	-
AADI BIOSCIENCE, INC. CIN: 4459056 , United States, Active	Sep 29, 2011	$10M - $50M (As on Dec 31, 2023)	-	-
AADI BIOSCIENCE, INC. CIN: 32092440125 , United States, Active	Nov 06, 2023	-	-	-

Aadi Bioscience got listed on Aug 08, 2017.

Click here to take a look at Aadi Bioscience's IPO in detail

Aadi Bioscience has raised a total funding of $23M over 5 rounds. Its first funding round was on Sep 26, 2012. Aadi Bioscience has 15 institutional investors.

Here is the list of recent funding rounds of Aadi Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2025	7205323	Post IPO	1123642	2625576	7458931	5065829
Sep 22, 2022	4424077	Post IPO	7642138	9993606	3451274	Avoro Capital & 4 more
Jul 15, 2017	8603237	Grant (prize money)	4117388	6154508	4611302	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Aadi Bioscience's funding rounds and investors

Aadi Bioscience's employee count trend

Aadi Bioscience has 55 employees as of Jul 26. Here is Aadi Bioscience's employee count trend over the years:

Employee count trend for Aadi Bioscience

Uncover Aadi Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aadi Bioscience include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Aadi Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
88th	Aadi Bioscience 2008, Los Angeles (United States), Public	Precision medicine company improving lives with mTOR-driven disease therapies	$23M	Celgene, Avoro Capital & 13 others	53/100